JP7339471B1 - 癌転移抑制用のvipr2アンタゴニストペプチド - Google Patents

癌転移抑制用のvipr2アンタゴニストペプチド Download PDF

Info

Publication number
JP7339471B1
JP7339471B1 JP2023528145A JP2023528145A JP7339471B1 JP 7339471 B1 JP7339471 B1 JP 7339471B1 JP 2023528145 A JP2023528145 A JP 2023528145A JP 2023528145 A JP2023528145 A JP 2023528145A JP 7339471 B1 JP7339471 B1 JP 7339471B1
Authority
JP
Japan
Prior art keywords
vipr2
cells
peptide
cancer
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023528145A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023162456A1 (cg-RX-API-DMAC7.html
JPWO2023162456A5 (cg-RX-API-DMAC7.html
Inventor
由希夫 吾郷
智志 浅野
孝太郎 坂元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hiroshima University
Ichimaru Pharcos Co Ltd
Original Assignee
Hiroshima University
Ichimaru Pharcos Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiroshima University, Ichimaru Pharcos Co Ltd filed Critical Hiroshima University
Publication of JPWO2023162456A1 publication Critical patent/JPWO2023162456A1/ja
Application granted granted Critical
Publication of JP7339471B1 publication Critical patent/JP7339471B1/ja
Publication of JPWO2023162456A5 publication Critical patent/JPWO2023162456A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023528145A 2022-02-25 2022-12-26 癌転移抑制用のvipr2アンタゴニストペプチド Active JP7339471B1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022027791 2022-02-25
JP2022027791 2022-02-25
PCT/JP2022/047969 WO2023162456A1 (ja) 2022-02-25 2022-12-26 癌転移抑制用のvipr2アンタゴニストペプチド

Publications (3)

Publication Number Publication Date
JPWO2023162456A1 JPWO2023162456A1 (cg-RX-API-DMAC7.html) 2023-08-31
JP7339471B1 true JP7339471B1 (ja) 2023-09-05
JPWO2023162456A5 JPWO2023162456A5 (cg-RX-API-DMAC7.html) 2024-01-30

Family

ID=87765588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528145A Active JP7339471B1 (ja) 2022-02-25 2022-12-26 癌転移抑制用のvipr2アンタゴニストペプチド

Country Status (5)

Country Link
US (1) US20250186540A1 (cg-RX-API-DMAC7.html)
EP (1) EP4473973A4 (cg-RX-API-DMAC7.html)
JP (1) JP7339471B1 (cg-RX-API-DMAC7.html)
CN (1) CN118742316A (cg-RX-API-DMAC7.html)
WO (1) WO2023162456A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021200259A1 (ja) * 2020-03-30 2021-10-07 一丸ファルコス株式会社 Vipr2アンタゴニストペプチド

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021200259A1 (ja) * 2020-03-30 2021-10-07 一丸ファルコス株式会社 Vipr2アンタゴニストペプチド

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
LEE Y. et al.,Up-regulation of PI3K/Akt signaling by 17β-estradiol through activation of estrogen receptor-α, but not estrogen receptor-β, and stimulates cell growth in breast cancer cells,Biochemical and Biophysical Research Communications,2005年,336,pp. 1221-1226
LEE Y. ET AL.: "Up-regulation of PI3K/Akt signaling by 17β-estradiol through activation of estrogen receptor-α, bu", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 336, JPN6023010204, 2005, pages 1221 - 1226, XP027230305, ISSN: 0005120289, DOI: 10.1016/j.bbrc.2005.08.256 *
SAKAMOTO K. et al.,Generation of KS-133 as a novel bicyclic peptide with a potent and selective VIPR2 antagonist activity that counteracts cognitive decline in a mouse model of psychiatric disorders,Front Pharmacol.,2021年,12,Article 751587, pp.1-15
SAKAMOTO K. ET AL.: "Generation of KS-133 as a novel bicyclic peptide with a potent and selective VIPR2 antagonist activi", FRONT PHARMACOL., vol. 12, JPN6023010202, 2021, pages 751587 - 1, ISSN: 0005120288 *
河原崎 哲, 他5名,癌抑制遺伝子PTENの機能解析,Biotherapy,2004年,18(2),pp.151-160
河原崎 哲, 他5名: "癌抑制遺伝子PTENの機能解析", BIOTHERAPY, vol. 18(2), JPN6023010203, 2004, pages 151 - 160, ISSN: 0005120290 *
浅野 智志, 吾郷 由希夫,神経ペプチドVIP-VPAC2 受容体シグナルは,がん細胞遊走を制御する新規の分子機構である,J Oral Biosci.,2021年,Suppl.,p.282, 3-P1-P77
浅野 智志, 吾郷 由希夫: "神経ペプチドVIP-VPAC2 受容体シグナルは,がん細胞遊走を制御する新規の分子機構である", J ORAL BIOSCI., vol. Suppl., JPN6023010201, 2021, pages 282 - 3, ISSN: 0005120287 *

Also Published As

Publication number Publication date
EP4473973A1 (en) 2024-12-11
WO2023162456A1 (ja) 2023-08-31
JPWO2023162456A1 (cg-RX-API-DMAC7.html) 2023-08-31
CN118742316A (zh) 2024-10-01
US20250186540A1 (en) 2025-06-12
EP4473973A4 (en) 2026-01-21

Similar Documents

Publication Publication Date Title
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
JP4335910B2 (ja) メタスチン誘導体およびその使用
WO2004063221A1 (ja) メタスチン誘導体およびその用途
WO2015056713A1 (ja) c-Metタンパク質アゴニスト
JP2025036429A (ja) プロテアーゼ活性化受容体2のモジュレーター
US20210361741A1 (en) Nanoparticle formulations and methods of use for alpha connexin c-terminal peptides
JPWO2017204219A1 (ja) ペプチド化合物
JP2021510538A (ja) タンパク質性分子およびその使用
CN111032069A (zh) Piezo调节剂在制备药物中的用途
WO2020230780A1 (ja) Ras阻害ペプチド
US20240391887A1 (en) New VASHs inhibitors, conjugates thereof and their uses as drugs or as research tools
JP6735676B2 (ja) C−fosの選択的インヒビターおよびその抗増殖特性
WO2023162456A1 (ja) 癌転移抑制用のvipr2アンタゴニストペプチド
JP7417010B1 (ja) 癌免疫増強用のvipr2アンタゴニストペプチド
JP7698318B2 (ja) Vipr2アンタゴニストペプチド
CN106170492B (zh) 环状的Apelin类似物
JP7781422B2 (ja) Cb1受容体アゴニストの副作用を軽減するペプチド化合物
US20230374103A1 (en) Wnt SIGNALING PATHWAY INHIBITOR
JP2011512364A (ja) 治療用ペプチド
US20060083742A1 (en) Prenyl-electrostatic switch, and methods of use
JP7341451B2 (ja) タンパク質性化合物とその利用
US20210395310A1 (en) Cyclic Peptide
JP7713129B1 (ja) 組成物
WO2013113060A1 (en) Peptide
WO2026096966A1 (en) Beta-catenin nuclear transport inhibitors and methods using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230510

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20230510

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20230511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230822

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230824

R150 Certificate of patent or registration of utility model

Ref document number: 7339471

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D03

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250